Whisker Sells One Millionth Robot and Completes Its $10M USA Manufacturing Expansion

The Global Leader in Connected Pet Care Continues Unprecedented Growth as it Maintains Laser Focus on Developing Best-in-Class, Solution-Oriented Pet Products

Whisker, the international leader in connected pet care for the past 22 years, sold its millionth Robot (Litter-Robot and Feeder-Robot) in December, marking a major milestone for the company as it continues to develop new technologies to solve pain points for today’s pet parents. The landmark sale culminates several years of remarkable growth for the brand.

This year alone, the brand launched the latest Litter-Robot iteration, Litter-Robot 4, completed a $10-million investment in U.S. warehouse expansions in Juneau, Wisconsin, and grew its team to over 400 US-based employees with 40+ engineers.

As the leading innovator within the pet care and pet tech space, the Whisker Team proudly designs, engineers and assembles its pet robot appliances in the USA, providing beautiful, solution-oriented products to make pet parenting more enjoyable. Every product is carefully developed and undergoes rigorous testing to meet the high standards of cats and pet parents alike.

The Litter-Robot 4 was meticulously designed by the Whisker Team, taking more than 20 years of product innovation and experience into consideration. Key features of the latest self-cleaning litter box include its patented connected app, health-monitoring technology, and yet another evolution of the brand’s patented litter-sifting mechanism, among additional features that enhance the cat care experience. Since launching in May, Litter-Robot 4 sales have exceeded expectations and generated glowing reviews from press including recognition from TIME Magazine, Wall Street Journal and more. The company’s impressive growth trajectory over the past 5 years was also featured in a profile and daily cover in Forbes in the last month.

“As the global leader in connected pet care and the inventors of the best selling automatic globe-sifting litter box, Litter-Robot,, we take great pride in leading the smart pet tech category to transform cat parenthood for the better, and the sale of our millionth robot is just the start to Whisker doing just that,” said Whisker President and CEO, Jacob Zuppke. “As we reflect on the success of the past several years, including our recent $10M investment to expand our U.S. based manufacturing facility, we’re eager to build on this continued momentum and further enhance the pet and pet parenting experience across the globe.”

This June, Whisker completed its $10 million investment to expand its U.S. manufacturing facility in Juneau, Wisconsin, further demonstrating the brand’s commitment to domestic manufacturing. The opening of the impressive 162,500 square foot facility allowed for the creation of 100+ new jobs, with an expected 200 more in the next two years. The new facility will allow Whisker to continue leading the pet tech industry in both quality and design – guaranteeing Litter-Robot, Feeder-Robot and Litterbox.com customers the best and most ethically-made pet care products here in the USA.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.